PHOENIX, April 15, 2019 — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company.Continue reading
Phoenix, Arizona: bioSyntagma has been named a finalist for the competitive Katerva Awards, which recognize disruptive innovations in global sustainability. This comes after bioSyntagma’s recent debut of their mPrint Mind™, an artificial intelligence for screening cancer patients.Continue reading
Arizona researchers are playing a key role in the search for new ways to identify CTE before death. In a study released online in the New England Journal of Medicine, a cross-national team, including local researchers from Arizona State University, Banner Alzheimer’s Institute, the Mayo Clinic College of Medicine, and Boston University have brought us a step closer to diagnosing CTE in living, former NFL players.Continue reading
Washington, D.C. (April 3, 2019) – Senator Kyrsten Sinema was recognized today by the Biotechnology Innovation Organization (BIO) for her leadership as an Innovator in Biotechnology. Senator Sinema received the award in conjunction with today’s BIO Legislative Day Fly-In.Continue reading
While antibiotic resistance is on the rise, pharmaceutical companies are making fewer and fewer new antibiotics. UA immunobiologist Michael Johnson says this trend is in urgent need of reversal and believes copper might just be the key.Continue reading
The Flinn Foundation and The Arizona Republic have entered into a grant-based partnership that will enable the state’s largest media platform to pursue a multimedia initiative to deepen public understanding of the biosciences in Arizona, including research, industry development, and clinical advances.Continue reading
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and Europe. Continue reading
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced that Stryker’s Chairman and CEO Kevin Lobo has been named chairman of the AdvaMed Board of Directors for a two-year term.